You can buy or sell Chimerix and other stocks, options, ETFs, and crypto commission-free!
Chimerix, Inc. Common Stock, also called Chimerix, is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Read More Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
Durham, North Carolina
52 Week High
52 Week Low
Simply Wall StMar 7
Some Chimerix Shareholders Have Taken A Painful 93% Share Price Drop
Long term investing works well, but it doesn’t always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Chimerix, Inc. (NASDAQ:CMRX) for five years would be nursing their metaphorical wounds since the share price dropped 93% in that time. And it’s not just long term holders hurting, because the stock is down 66% in the last year. Shareholders have had an even rougher run lately, with the share price down 43% in the last 90 days. This could be r...
Stock Price, News, & Analysis for Chimerix
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a ...
Expected May 7, Pre-Market